Medidata announced that ONO PHARMACEUTICAL CO., LTD has expanded its adoption of the Medidata Clinical Cloud® to include all clinical trials testing the use of OPDIVO® (nivolumab) against a broad range of cancers. The company will leverage Medidata's electronic data capture and management technology (Medidata Rave®) to evaluate additional indications for OPDIVO, a cutting-edge immunotherapy drug that was initially approved to treat metastatic melanoma.
1st Jan change | Capi. | |
---|---|---|
-18.30% | 180B | |
+1.02% | 166B | |
+3.46% | 155B | |
+4.14% | 99.3B | |
+50.96% | 93.8B | |
+14.41% | 84.11B | |
-3.50% | 73.81B | |
-2.39% | 46.39B | |
-36.10% | 42.58B |